Acyl-coenzyme A: cholesterol acyltransferase-1 and -2 (ACAT-1 and ACAT-2) catalyze the formation of cholesterolesters from cholesterol and long chain fatty acyl-coenzyme A, and may play a role in the development of atherosclerosis. CAY10485 inhibits human ACAT-1 and ACAT-2 with an IC50 values of 95 and 81 μM, respectively. It also inhibits copper-mediated oxidation of low density lipoproteins by 91% at a concentration of 2 μM.
Acyl-Coenzyme A: cholesterol acyltransferase-1 and -2 (ACAT-1 and ACAT-2) catalyze the formation of cholesterolesters from cholesterol and long chain fatty acyl-coenzyme A, and may play a role in the development of atherosclerosis. CAY10486 inhibits human ACAT-1 and ACAT-2 equally with an IC50 value of approximately 60 μM. It also inhibits copper-mediated oxidation of low density lipoproteins by about 28% at a concentration of 3 μM.
Cholesteryl heptadecanoate is a cholesterol ester (CE) formed by the condensation of cholesterol with heptadecanoic acid, a C-17 saturated fatty acid that does not occur in any natural animal or vegetable fat at high concentrations. As such, it is commonly used as an internal standard for the quantification of cholesterolesters by GC- or LC-mass spectrometry. CEs are major constituents of lipoprotein particles carried in blood and accumulate in the fatty acid lesions of atherosclerotic plaques. CEs of various fatty acids are major constituents of murine and human adrenal glands.
Cholesteryl palmitoleate, a cholesterol ester, exhibits elevated plasma levels in ApoE- - mice following exposure to cigarette smoke and in pediatric patients diagnosed with biliary atresia. It serves as a standard for identifying cholesterolesters in human meibomian gland secretions.